關於 adpkd tolvaptan ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Autosomal dominant polycystic kidney disease (ADPKD)

Polycystic kidney disease (PKD) includes inherited diseases that cause an irreversible decline in kidney function. PKD is most commonly ...

#12. Tolvaptan in ADPKD Patients With Very Low Kidney Function

Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and ...

#13. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Tolvaptan is an approved treatment for use against ADPKD. The results of various clinical trials showed that tolvaptan is the drug of choice in ...

#14. Treatment persistence to tolvaptan in patients with autosomal ...

Tolvaptan is the only available disease-modifying treatment for autosomal dominant polycystic kidney disease (ADPKD). Prior to October 2020 ...

#15. Real clinical experience after one year of treatment with ...

Background: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney ...

#16. 長庚醫訊 長庚紀念醫院

何為多囊腎自體顯性多囊腎(Autosomal Dominant Polycystic Kidney disease, ... 台灣食品及藥物管理局核准Tolvaptan的治療需由腎臟科專科醫師處方且需事先審查核准後 ...

#17. Autosomal dominant polycystic kidney disease - Treatment

Tolvaptan is a medication that's recommended by the National Institute for Health and Care Excellence (NICE) to treat ADPKD in adults.

#18. 淺談體染色體顯性多囊性腎臟病／吳秋玫 - 藥學雜誌電子報150期

在TEMPO（Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes）試驗中，包括1157例eGFR> ...

#19. Treatment for Rapidly Progressing ADPKD | JYNARQUE ...

JYNARQUE® (tolvaptan) is proven to slow kidney function decline in adults who are at risk for rapidly progressing ADPKD. Learn more about JYNARQUE.

#20. Long-Term Effects of High-Dose Tolvaptan for Autosomal ...

The efficacy of tolvaptan at a daily dose of 60–120 mg for ADPKD patients has been confirmed by results of 2 different pivotal trials [6, 7]. In ...

#21. Potential effect of tolvaptan on polycystic liver disease ... - PLOS

Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes ...

#22. REPRISE: tolvaptan in advanced polycystic kidney disease

REPRISE confirms the efficacy of tolvaptan in slowing eGFR decline in ADPKD, a key secondary endpoint of TEMPO, and extends the results of TEMPO to patients ...

#23. Recent updates in therapeutic approach using tolvaptan for ...

cAMP, cyclic AMP; PKD, polycystic kidney disease; TEMPO, Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes; REPRISE, ...

#24. Tolvaptan and Kidney Function Decline in Older Individuals ...

Tolvaptan is indicated for treatment of patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression.

#25. The Effect of Dietary Intervention on Autosomal-Dominant ...

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life. Ola ...

#26. Treatment options - PKD Charity

It can slow the rate at which your kidneys become enlarged by cysts and can help to slow the speed at which your kidney function declines. Tolvaptan does not ...

#27. Acute Response to Tolvaptan in ADPKD: A Window to Predict ...

In addition to its effect on cyst growth, tolvaptan may help slow the progression of kidney disease in ADPKD by decreasing glomerular hyperfiltration. In ...

#28. Tolvaptan for treating autosomal dominant polycystic kidney ...

Patients aged. 18–50 years with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) and an estimated glomerular filtration rate. (eGFR) of ...

#29. Pooled Data Analysis of the Long-Term Treatment Effects of ...

In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease ...

#30. Drug management of autosomal dominant polycystic kidney ...

Tolvaptan is a specific oral vasopressin type 2 receptor antagonist and is indicated in patients with ADPKD at high risk of developing ...

#31. 1 Renal Association Working Group on Tolvaptan in ADPKD

Renal Association Working Group on Tolvaptan in ADPKD. Page 2. 2. Page 3. 3. Page 4. 4. Page 5. 5. > evidence. Evidence. Page 6. 6 risk. Page 7 ...

#32. ADPKD Classification

CLASSIFICATION OF TYPICAL ADPKD CALCULATOR. END USER LICENSE AGREEMENT. IMPORTANT LEGAL NOTICE TO ALL USERS: CAREFULLY READ THE FOLLOWING LEGAL AGREEMENT ...

#33. Will introduction of tolvaptan change clinical practice ... - KDIGO

The vasopressin inhibitor tolvaptan is clinically effective in slowing ... rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD),.

#34. Pooled data analysis of the long-term effect of Tolvaptan in ...

INTRODUCTION: This analysis aimed to assess the effect of tolvaptan (TOL) ... 56 and 65 years with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

#35. Otsuka's JYNARQUE™ (tolvaptan) Approved by U.S. FDA as ...

ADPKD is a genetic disease with consequences that can lead to dialysis or kidney transplantation. It is a progressively debilitating and often ...

#36. Transcriptomic and metabolic profiling of Tolvaptan treated ...

Currently, dialysis or a transplant are the only treatments for end-stage ADPKD patients. Tolvaptan is a is a selective vasopressin V2-receptor ...

#37. Efficacy and safety of tolvaptan versus placebo in the ...

Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is a single-gene disease and the most common inherited progressive kidney ...

#38. Jinarc® (Tolvaptan) – New drug for treatment for Autosomal ...

Jinarc® (Tolvaptan) – New drug for treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Risk of Liver Injury.

#39. Clinical Implication of Tolvaptan in Patients with Autosomal ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease characterized by the growth of numerous fluid- ...

#40. Tolvaptan in Polycystic Kidney Disease - NHS Ayrshire & Arran

Tolvaptan is a new drug that can be used in adults with autosomal dominant polycystic kidney disease. (PKD). Tolvaptan slows down the damage to the kidneys.

#41. Tolvaptan in Patients with ADPKD: Post Hoc Analysis of the ...

Patients with ADPKD are treated with tolvaptan, a selective V2 receptor antagonist, which has been shown to slow the rate of disease ...

#42. Autosomal-dominant polycystic kidney disease: tolvaptan use ...

Tolvaptan slows the increase in total kidney volume in patients aged 18–24 years with ADPKD. Tolvaptan posed no risk of potential liver injury ...

#43. Jinarc/Tolvaptan in the treatment of Polycystic Kidney Disease

JINARC (Tolvaptan) has been recently approved in Australia for the treatment of polycystic kidney disease in patients with declining renal function.

#44. Acute Effects of Tolvaptan on Renal Hemodynamics in ...

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by formation of cysts in the kidneys, causing gradual renal ...

#45. Assessment report - Jinarc - European Medicines Agency |

A new application for tolvaptan in the treatment of ADPKD was filed in the ... Autosomal dominant polycystic kidney disease (ADPKD, previously known as ...

#46. Tolvaptan for autosomal dominant polycystic kidney disease

Tolvaptan is only indicated to slow the progression of cyst development and renal insufficiency of ADPKD in adults with chronic kidney ...

#47. Application for Tolvaptan in ADPKD - BC Renal

*Confirmed diagnosis of ADPKD: □ Yes □ No. Tolvaptan is only indicated for use in ADPKD and not in any other renal cystic disease. Current patient ...

#48. A Case Report of Tolvaptan Therapy for ADPKD Patients With ...

Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) may require specific therapy with vasopressin receptor antagonists to slow the ...

#49. Tolvaptan for patients with ADPKD by Dr. Lazowski

Tolvaptan has received clearance for a treatment of autosomal dominant polycystic kidney disease (ADPKD) in adults. The drug is marketed as Jynarque by ...

#50. Search Orphan Drug Designations and Approvals - FDA

Generic Name: tolvaptan ... to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

#51. Management of ADPKD in the era of tolvaptan

The hallmark of autosomal dominant polycystic kidney disease (ADPKD) is numerous, fluid-filled cysts that derive from the entire nephron located ...

#52. Regional Variance of the Early Use of Tolvaptan for Autosoma...

In Japan, high-dose tolvaptan tablets were approved as the first drug for autosomal dominant polycystic kidney disease (ADPKD) in 2014.

#53. Tolvaptan by Otsuka Pharmaceutical for Polycystic Kidney ...

Tolvaptan is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease ( ...

#54. Older patients with autosomal dominant PKD may benefit from ...

“Tolvaptan is the only disease-specific treatment for [autosomal dominant PKD] ADPKD and is indicated to slow kidney function decline in ...

#55. Tolvaptan for Adult Polycystic Kidney Disease (ADPKD)

Tolvaptan is a drug specifically for the treatment of adult polycystic kidney disease (ADPKD). It has been approved for use in the NHS by The National Institute ...

#56. FDA OKs Tolvaptan for Rapidly Progressing Rare Kidney ...

ADPKD is a rare, chronic, progressive, inherited disease that causes the proliferation and growth of cysts in the kidneys, leading to an ...

#57. 血液透析大小事| #Tolvaptan對ADPKD的長期治療使血壓逐漸降低

Tolvaptan 對ADPKD的長期治療使血壓逐漸降低，可能歸因於#對疾病進展的有益作用或持續的利鈉作用(sustained #natriuretic)#或兩者。 Tolvaptan 對多囊性腎病血壓的 ...

#58. Long-term Tolvaptan Treatment of Autosomal Dominant ...

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder, but there are no effective treatments till date. Tolvaptan, a ...

#59. Autosomal dominant polycystic kidney disease (ADPKD)

saroarakelians #pharmacisteducationcorner #autosomaldominant #polycysticovarysyndrome #kidney #kidneydisease#jynarque# tolvaptan #Otsuka.

#60. NICE recommends tolvaptan for patients with ADPKD

People living with autosomal dominant polycystic kidney disease (ADPKD) in England and Wales will now have access to Otsuka's Jinarc (tolvaptan) ...

#61. Tolvaptan (Oral Route) Proper Use - Mayo Clinic

For slowing kidney function decline in patients who are at risk of autosomal dominant polycystic kidney disease (ADPKD):. Adults—At first, 60 milligrams ...

#62. Treating Autosomal Dominant Polycystic Kidney Disease with ...

In April 2018 the FDA approved tolvaptan (Jynarque) as a treatment to help slow kidney function decline in adults who are at risk of rapidly ...

#63. Recent Advances in the Management of Autosomal Dominant ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most ... 을 평가하는 tolvaptan efficacy and safety in management of autosomal ...

#64. Open-label, Extension Study of Oral Tolvaptan Tablet ...

Research summary. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder characterised by the formation oflud-filled cysts in the kidneys.

#65. Management of autosomal dominant polycystic kidney ...

... cases and development of disease-modifying treatment options such as tolvaptan. This review highlights the genetic mutations associated with ADPKD, ...

#66. Tolvaptan Delays the Onset of End-Stage Renal Disease in a ...

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2 genes, which encode polycystin-1 and polycystin-2 ...

#67. Effects of Tolvaptan on Oxidative Stress in ADPKD - MDPI

Autosomal dominant polycystic disease (ADPKD) is the most frequent monogenic kidney disease. It causes progressive renal failure, endothelial dysfunction, ...

#68. Taking Tolvaptan for ADPKD - YourHealth - Leicester's Hospitals

Tolvaptan is available to certain NHS patients who have 'rapidly progressing ADPKD and who have chronic kidney disease stage 2 or 3'. Speak to your doctor if ...

#69. Tolvaptan in ADPKD Patients With Very Low Kidney Function

Introduction: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with auto- somal dominant polycystic kidney disease (ADPKD) ...

#70. Long-Term Benefits of Treatment with Tolvaptan in Patients ...

Background: Tolvaptan is the first effective drug treatment for autosomal dominant polycystic kidney disease (ADPKD) patients, but few long-term ...

#71. Tolvaptan for Polycystic Kidney Disease (PKD) - Vimeo

This video is for information only, it is not a substitute for medical advice. If you think you may have an issue with your health, ...

#72. Homepage | SAMSCA® (tolvaptan)

WARNING: NOT FOR USE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). Because of the risk of hepatotoxicity, tolvaptan should not be used for ADPKD ...

#73. 接受托伐普坦治疗的常染色体显性多囊肾病患者的心 ... - X-MOL

Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study

#74. COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN ...

PUK16 - COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN PATIENTS WITH AUTOSOMAL POLYCYSTIC KIDNEY DISEASE: AN ADAPTATION OF THE ADPKD OUTCOMES MODEL.

#75. tolvaptan (Jinarc) - Scottish Medicines Consortium

tolvaptan (Jinarc®) is accepted for use within NHS Scotland. ... dominant polycystic kidney disease (ADPKD) in adults with chronic kidney ...

#76. HSE Managed Access Protocol Tolvaptan (Jinarc)

ADPKD. Autosomal dominant polycystic kidney disease. ALT. Alanine transaminase. AST. Aspartate aminotransferase. BT. Bilirubin-total.

#77. ADPKD – Landmark Nephrology

Kidney volume correlates with disease progression. 2010. EVEROLIMUS IN PKD. Everolimus vs placebo. 2012. TEMPO 3:4. Tolvaptan vs placebo. Early CKD GFR>60.

#78. Tolvaptan: a Possible Treatment for Autosomal Dominant ...

Background: Background: Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited renal cystic disease that leads to end-stage renal disease.

#79. Otsuka Announces Positive Phase III Data on Tolvaptan, in ...

... Positive Phase III Data on Tolvaptan, in Development in U.S. for ADPKD ... of tolvaptan in autosomal dominant polycystic kidney disease ...

#80. A practical guide for treatment of rapidly progressive ADPKD ...

Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly ...

#81. Aquaretic Treatment in Polycystic Kidney Disease

with delayed progression of ADPKD in a phase 2 clinical study.2. In the Tolvaptan Efficacy and Safety in Man- agement of Autosomal Dominant ...

#82. Tolvaptan inhibits ERK-dependent cell proliferation, Cl

In autosomal dominant polycystic kidney disease (ADPKD), arginine vasopressin (AVP) accelerates cyst growth by stimulating cAMP-dependent ERK activity and ...

#83. Tolvaptan in Patients with Autosomal ... - IRIS Unimore

The course of autosomal dominant polycystic kidney disease (ADPKD) is often associ- ated with pain, hypertension, and kidney failure.

#84. Efficacy of tolvaptan in reduction of kidney cyst volume and ...

Background: Autosomal dominant polycystic kidney disease (ADPKD) is a frequent cause of end-stage renal disease. Despite improvements in blood ...

#85. Tolvaptan Cleared in US for ADPKD in Adults

Tolvaptan has received FDA marketing clearance as a treatment for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) ...

#86. Predicting Polyuria: Can We Help Patients with ADPKD Better ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most common ... Thus, it is exciting that tolvaptan, a vasopressin V2 receptor ...

#87. 多囊腎，使用Tolvaptan好嗎? - 陳鋭溢

另一位是是29歲多囊腎的女性(autosomal dominant polycystic kidney disease; ADPKD)，腎絲球過濾率113ml/min，腎臟體積1216毫升(total kidney volume, ...

#88. Tolvaptan for the treatment of Adult Polycystic Kidney Disease ...

ADPKD cannot be cured; however, it is possible to slow the onset of kidney failure through medication. Tolvaptan blocks the effects of the hormone vasopressin.

#89. A Practical Guide for Treatment of Rapidly Progressive ...

Practical guidance is provided and steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure ...

#90. Trial of Tolvaptan in ADPKD, REPRISED: The Visual ...

Two Visual Abstracts for the the tolvaptan in ADPKD REPRISE trial.

#91. Tolvaptan in Polycystic Kidney Disease (ADPKD): the most ...

The High Impact Clinical Trials Session at this year's American Society of Nephrology Renal Week was the site of one of the most important ...

#92. Landmark Trials in ADPKD: Close, But No Cigar

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease, ... Visual Abstract: Tolvaptan and Progression of ADPKD.

#93. Patients Report Effects of Tolvaptan on ADPKD - Patient Worthy

Patients Report Effects of Tolvaptan on ADPKD · What is ADPKD? ADPKD or autosomal dominant polycystic kidney disease is a genetic (inherited) disorder that ...

#94. Algorithm to assess indications for initiation of treatment in ...

Purpose: Tolvaptan is the first approved treatment for autosomal dominant polycystic kidney disease (ADPKD) that targets a mechanism directly contributing to ...

#95. Tolvaptan Use in Autosomal Dominant Polycystic Kidney ...

Autosomal dominant polycystic kidney damage (ADPKD) is one of the most common and potentially deadly forms of polycystic kidney disease; it is ...

#96. Treatment Updates in ADPKD - VuMedi

Polycystic Kidney Disease : What Is the Efficacy of Tolvaptan, and How Does It Compare to Other Renal Protective Therapies? By Keck School of Medicine of USC ...

#97. NEJM：托伐坦用于多囊肾病效果佳 - 梅斯医学

Tags: 多囊肾 Tolvaptan 肾病 作者：NEJM 更新：2012-12-25 ... 随着常染色体显性多囊肾病（ADPKD）的病情进展，患者常并发疼痛、高血压和肾功能衰竭。